- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT04394858
Тестирование добавления противоракового препарата олапариба к обычной химиотерапии (темозоломид) при прогрессирующем нейроэндокринном раке
Проспективное межведомственное исследование фазы II по оценке темозоломида в сравнении с темозоломидом и олапарибом при распространенной феохромоцитоме и параганглиоме
This phase II trial studies how well the addition of olaparib to the usual treatment, temozolomide, works in treating patients with neuroendocrine cancer (pheochromocytoma or paraganglioma) that has spread from where it first started (primary site) to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Poly (adenosine diphosphate [ADP]-ribose) polymerases (PARPs) are proteins that help repair deoxyribonucleic acid (DNA) mutations. PARP inhibitors, such as olaparib, can keep PARP from working, so tumor cells can't repair themselves, and they may stop growing. Chemotherapy drugs, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving olaparib with temozolomide may shrink or stabilize the cancer in patients with pheochromocytoma or paraganglioma better than temozolomide alone.
Обзор исследования
Статус
Условия
- Метастатическая феохромоцитома надпочечников
- Метастатическая параганглиома
- Неоперабельная феохромоцитома надпочечника
- Неоперабельная параганглиома
- Расширенная феохромоцитома надпочечников
- Продвинутая параганглиома
- Стадия III Феохромоцитома надпочечников и симпатическая параганглиома AJCC v8
- Стадия IV Феохромоцитома надпочечников и симпатическая параганглиома AJCC v8
Подробное описание
PRIMARY OBJECTIVE:
I. To compare the progression-free survival (PFS) of patients with advanced pheochromocytoma and paraganglioma (APP) receiving temozolomide (dose dense) and olaparib to that of patients receiving temozolomide (pulse dose) alone.
SECONDARY OBJECTIVES:
I. To compare the overall survival (OS) of patients with APP receiving temozolomide (dose dense) and olaparib versus (vs.) temozolomide (pulse dose) alone.
II. To compare the objective response rate (ORR) associated with temozolomide (dose dense) and olaparib vs. temozolomide (pulse dose) alone in patients with APP.
III. To evaluate and compare the toxicity profile of temozolomide-based combinations (temozolomide [dose dense] and olaparib vs. temozolomide [pulse dose]) in patients with APP using Common Terminology Criteria for Adverse Events (CTCAE) and Patient-Reported Outcomes (PRO)-CTCAE.
OTHER OBJECTIVE:
I. Results of the primary analysis will be examined for consistency, while taking into account the stratification factors and/or covariates of baseline quality of life (QOL) and fatigue.
EXPLORATORY OBJECTIVES:
I. To assess biochemical response: serum catecholamines and metanephrines; urine catecholamines and metanephrines.
II. To assess biomolecular markers associated with clinical outcome: germline succinyl dehydrogenase (SDH) mutations and tumor status of the repair enzyme methylguanine-deoxyribonucleic acid (DNA) methyltransferase (MGMT).
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive temozolomide orally (PO) once daily (QD) and olaparib PO twice daily (BID) on days 1-7. Treatment with temozolomide repeats every 21 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Cycles of olaparib repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography (CT) with contrast or magnetic resonance imaging (MRI) throughout the study and undergo mandatory collection of blood samples prior to treatment. Patients may optionally undergo collection of blood samples at the time of progression.
ARM II: Patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with contrast or MRI throughout the study and undergo mandatory collection of blood samples prior to treatment. Patients may optionally undergo collection of blood samples at the time of progression.
Patients discontinuing treatment due to reasons other than disease progression are followed every 12 weeks until disease progression, then every 6 months until 5 years after registration. Patients discontinuing treatment due to disease progression are followed every 6 months for 5 years after registration.
Тип исследования
Регистрация (Оцененный)
Фаза
- Фаза 2
Контакты и местонахождение
Места учебы
-
-
Alaska
-
Anchorage, Alaska, Соединенные Штаты, 98508
- Anchorage Associates in Radiation Medicine
-
Anchorage, Alaska, Соединенные Штаты, 99508
- Alaska Breast Care and Surgery LLC
-
Anchorage, Alaska, Соединенные Штаты, 99508
- Alaska Oncology and Hematology LLC
-
Anchorage, Alaska, Соединенные Штаты, 99508
- Alaska Women's Cancer Care
-
Anchorage, Alaska, Соединенные Штаты, 99508
- Anchorage Oncology Centre
-
Anchorage, Alaska, Соединенные Штаты, 99508
- Katmai Oncology Group
-
Anchorage, Alaska, Соединенные Штаты, 99508
- Providence Alaska Medical Center
-
Anchorage, Alaska, Соединенные Штаты, 99504
- Anchorage Radiation Therapy Center
-
-
California
-
Burbank, California, Соединенные Штаты, 91505
- Providence Saint Joseph Medical Center/Disney Family Cancer Center
-
-
Florida
-
Fort Lauderdale, Florida, Соединенные Штаты, 33308
- Holy Cross Hospital
-
Gainesville, Florida, Соединенные Штаты, 32610
- UF Health Cancer Institute - Gainesville
-
-
Idaho
-
Boise, Idaho, Соединенные Штаты, 83712
- Saint Luke's Cancer Institute - Boise
-
Fruitland, Idaho, Соединенные Штаты, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Соединенные Штаты, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Соединенные Штаты, 83687
- Saint Luke's Cancer Institute - Nampa
-
Twin Falls, Idaho, Соединенные Штаты, 83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Bloomington, Illinois, Соединенные Штаты, 61704
- Illinois CancerCare-Bloomington
-
Canton, Illinois, Соединенные Штаты, 61520
- Illinois CancerCare-Canton
-
Carthage, Illinois, Соединенные Штаты, 62321
- Illinois CancerCare-Carthage
-
Centralia, Illinois, Соединенные Штаты, 62801
- Centralia Oncology Clinic
-
Chicago, Illinois, Соединенные Штаты, 60637
- University of Chicago Comprehensive Cancer Center
-
Danville, Illinois, Соединенные Штаты, 61832
- Carle at The Riverfront
-
Decatur, Illinois, Соединенные Штаты, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Dixon, Illinois, Соединенные Штаты, 61021
- Illinois CancerCare-Dixon
-
Effingham, Illinois, Соединенные Штаты, 62401
- Crossroads Cancer Center
-
Effingham, Illinois, Соединенные Штаты, 62401
- Carle Physician Group-Effingham
-
Eureka, Illinois, Соединенные Штаты, 61530
- Illinois CancerCare-Eureka
-
Galesburg, Illinois, Соединенные Штаты, 61401
- Illinois CancerCare-Galesburg
-
Kewanee, Illinois, Соединенные Штаты, 61443
- Illinois CancerCare-Kewanee Clinic
-
Macomb, Illinois, Соединенные Штаты, 61455
- Illinois CancerCare-Macomb
-
Mattoon, Illinois, Соединенные Штаты, 61938
- Carle Physician Group-Mattoon/Charleston
-
New Lenox, Illinois, Соединенные Штаты, 60451
- UC Comprehensive Cancer Center at Silver Cross
-
O'Fallon, Illinois, Соединенные Штаты, 62269
- Cancer Care Center of O'Fallon
-
Orland Park, Illinois, Соединенные Штаты, 60462
- University of Chicago Medicine-Orland Park
-
Ottawa, Illinois, Соединенные Штаты, 61350
- Illinois CancerCare-Ottawa Clinic
-
Pekin, Illinois, Соединенные Штаты, 61554
- Illinois CancerCare-Pekin
-
Peoria, Illinois, Соединенные Штаты, 61615
- Illinois CancerCare-Peoria
-
Peru, Illinois, Соединенные Штаты, 61354
- Illinois CancerCare-Peru
-
Princeton, Illinois, Соединенные Штаты, 61356
- Illinois CancerCare-Princeton
-
Urbana, Illinois, Соединенные Штаты, 61801
- Carle Cancer Center
-
Washington, Illinois, Соединенные Штаты, 61571
- Illinois CancerCare - Washington
-
-
Maryland
-
Bethesda, Maryland, Соединенные Штаты, 20892
- National Institutes of Health Clinical Center
-
-
Massachusetts
-
Boston, Massachusetts, Соединенные Штаты, 02215
- Dana-Farber Cancer Institute
-
Newton, Massachusetts, Соединенные Штаты, 02467
- Dana-Farber Cancer Institute - Chestnut Hill
-
-
Michigan
-
Ann Arbor, Michigan, Соединенные Штаты, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Brighton, Michigan, Соединенные Штаты, 48114
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Brighton, Michigan, Соединенные Штаты, 48114
- Trinity Health Medical Center - Brighton
-
Canton, Michigan, Соединенные Штаты, 48188
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Canton, Michigan, Соединенные Штаты, 48188
- Trinity Health Medical Center - Canton
-
Caro, Michigan, Соединенные Штаты, 48723
- Caro Cancer Center
-
Chelsea, Michigan, Соединенные Штаты, 48118
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Chelsea, Michigan, Соединенные Штаты, 48118
- Chelsea Hospital
-
Clarkston, Michigan, Соединенные Штаты, 48346
- Hematology Oncology Consultants-Clarkston
-
Clarkston, Michigan, Соединенные Штаты, 48346
- Newland Medical Associates-Clarkston
-
Detroit, Michigan, Соединенные Штаты, 48236
- Henry Ford Health Saint John Hospital
-
East China Township, Michigan, Соединенные Штаты, 48054
- Henry Ford River District Hospital
-
Flint, Michigan, Соединенные Штаты, 48503
- Hurley Medical Center
-
Flint, Michigan, Соединенные Штаты, 48503
- Genesee Hematology Oncology PC
-
Flint, Michigan, Соединенные Штаты, 48503
- Genesys Hurley Cancer Institute
-
Flint, Michigan, Соединенные Штаты, 48503
- Cancer Hematology Centers - Flint
-
Grosse Pointe Woods, Michigan, Соединенные Штаты, 48236
- Henry Ford Saint John Hospital - Academic
-
Grosse Pointe Woods, Michigan, Соединенные Штаты, 48236
- Henry Ford Saint John Hospital - Breast
-
Grosse Pointe Woods, Michigan, Соединенные Штаты, 48236
- Henry Ford Saint John Hospital - Van Elslander
-
Lansing, Michigan, Соединенные Штаты, 48912
- University of Michigan Health - Sparrow Lansing
-
Livonia, Michigan, Соединенные Штаты, 48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Livonia, Michigan, Соединенные Штаты, 48154
- Hope Cancer Clinic
-
Macomb, Michigan, Соединенные Штаты, 48044
- Henry Ford Warren Hospital - Breast Macomb
-
Macomb, Michigan, Соединенные Штаты, 48044
- Henry Ford Saint John Hospital - Macomb Medical
-
Marlette, Michigan, Соединенные Штаты, 48453
- Saint Mary's Oncology/Hematology Associates of Marlette
-
Pontiac, Michigan, Соединенные Штаты, 48341
- Hope Cancer Center
-
Pontiac, Michigan, Соединенные Штаты, 48341
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Pontiac, Michigan, Соединенные Штаты, 48341
- Michigan Healthcare Professionals Pontiac
-
Pontiac, Michigan, Соединенные Штаты, 48341
- Trinity Health IHA Medical Group-Alice Gustafson Center
-
Rochester Hills, Michigan, Соединенные Штаты, 48309
- Henry Ford Rochester Hospital
-
Saginaw, Michigan, Соединенные Штаты, 48604
- Oncology Hematology Associates of Saginaw Valley PC
-
Saginaw, Michigan, Соединенные Штаты, 48601
- MyMichigan Medical Center Saginaw
-
Sterling Heights, Michigan, Соединенные Штаты, 48312
- Bhadresh Nayak MD PC-Sterling Heights
-
Tawas City, Michigan, Соединенные Штаты, 48764
- MyMichigan Medical Center Tawas
-
Warren, Michigan, Соединенные Штаты, 48088
- Advanced Breast Care Center PLLC
-
Warren, Michigan, Соединенные Штаты, 48093
- Macomb Hematology Oncology PC
-
Warren, Michigan, Соединенные Штаты, 48093
- Henry Ford Madison Heights Hospital - Breast
-
Warren, Michigan, Соединенные Штаты, 48093
- Henry Ford Health Warren Hospital
-
Warren, Michigan, Соединенные Штаты, 48093
- Henry Ford Warren Hospital - GLCMS
-
West Branch, Michigan, Соединенные Штаты, 48661
- Saint Mary's Oncology/Hematology Associates of West Branch
-
Ypsilanti, Michigan, Соединенные Штаты, 48197
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
Ypsilanti, Michigan, Соединенные Штаты, 48106
- Huron Gastroenterology PC
-
-
Minnesota
-
Burnsville, Minnesota, Соединенные Штаты, 55337
- Fairview Ridges Hospital
-
Burnsville, Minnesota, Соединенные Штаты, 55337
- Minnesota Oncology - Burnsville
-
Cambridge, Minnesota, Соединенные Штаты, 55008
- Cambridge Medical Center
-
Coon Rapids, Minnesota, Соединенные Штаты, 55433
- Mercy Hospital
-
Edina, Minnesota, Соединенные Штаты, 55435
- Fairview Southdale Hospital
-
Fridley, Minnesota, Соединенные Штаты, 55432
- Unity Hospital
-
Maple Grove, Minnesota, Соединенные Штаты, 55369
- Fairview Clinics and Surgery Center Maple Grove
-
Maplewood, Minnesota, Соединенные Штаты, 55109
- Saint John's Hospital - Healtheast
-
Maplewood, Minnesota, Соединенные Штаты, 55109
- Minnesota Oncology Hematology PA-Maplewood
-
Minneapolis, Minnesota, Соединенные Штаты, 55415
- Hennepin County Medical Center
-
Minneapolis, Minnesota, Соединенные Штаты, 55407
- Abbott-Northwestern Hospital
-
Minneapolis, Minnesota, Соединенные Штаты, 55454
- Health Partners Inc
-
Monticello, Minnesota, Соединенные Штаты, 55362
- Monticello Cancer Center
-
New Ulm, Minnesota, Соединенные Штаты, 56073
- New Ulm Medical Center
-
Princeton, Minnesota, Соединенные Штаты, 55371
- Fairview Northland Medical Center
-
Robbinsdale, Minnesota, Соединенные Штаты, 55422
- North Memorial Medical Health Center
-
Rochester, Minnesota, Соединенные Штаты, 55905
- Mayo Clinic in Rochester
-
Saint Louis Park, Minnesota, Соединенные Штаты, 55416
- Park Nicollet Clinic - Saint Louis Park
-
Saint Paul, Minnesota, Соединенные Штаты, 55101
- Regions Hospital
-
Saint Paul, Minnesota, Соединенные Штаты, 55102
- United Hospital
-
Shakopee, Minnesota, Соединенные Штаты, 55379
- Saint Francis Regional Medical Center
-
Stillwater, Minnesota, Соединенные Штаты, 55082
- Lakeview Hospital
-
Waconia, Minnesota, Соединенные Штаты, 55387
- Ridgeview Medical Center
-
Willmar, Minnesota, Соединенные Штаты, 56201
- Rice Memorial Hospital
-
Woodbury, Minnesota, Соединенные Штаты, 55125
- Minnesota Oncology Hematology PA-Woodbury
-
Wyoming, Minnesota, Соединенные Штаты, 55092
- Fairview Lakes Medical Center
-
-
Missouri
-
Cape Girardeau, Missouri, Соединенные Штаты, 63703
- Saint Francis Medical Center
-
-
Montana
-
Missoula, Montana, Соединенные Штаты, 59802
- Saint Patrick Hospital - Community Hospital
-
-
New Jersey
-
Basking Ridge, New Jersey, Соединенные Штаты, 07920
- Memorial Sloan Kettering Basking Ridge
-
Middletown, New Jersey, Соединенные Штаты, 07748
- Memorial Sloan Kettering Monmouth
-
Montvale, New Jersey, Соединенные Штаты, 07645
- Memorial Sloan Kettering Bergen
-
-
New York
-
Albany, New York, Соединенные Штаты, 12208
- Albany Medical Center
-
Commack, New York, Соединенные Штаты, 11725
- Memorial Sloan Kettering Commack
-
Harrison, New York, Соединенные Штаты, 10604
- Memorial Sloan Kettering Westchester
-
New York, New York, Соединенные Штаты, 10065
- Memorial Sloan Kettering Cancer Center
-
Uniondale, New York, Соединенные Штаты, 11553
- Memorial Sloan Kettering Nassau
-
-
Ohio
-
Columbus, Ohio, Соединенные Штаты, 43210
- Ohio State University Comprehensive Cancer Center
-
-
Oklahoma
-
Lawton, Oklahoma, Соединенные Штаты, 73505
- Cancer Centers of Southwest Oklahoma Research
-
Oklahoma City, Oklahoma, Соединенные Штаты, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Bend, Oregon, Соединенные Штаты, 97701
- Saint Charles Health System
-
Clackamas, Oregon, Соединенные Штаты, 97015
- Clackamas Radiation Oncology Center
-
Clackamas, Oregon, Соединенные Штаты, 97015
- Providence Cancer Institute Clackamas Clinic
-
Coos Bay, Oregon, Соединенные Штаты, 97420
- Bay Area Hospital
-
Newberg, Oregon, Соединенные Штаты, 97132
- Providence Newberg Medical Center
-
Oregon City, Oregon, Соединенные Штаты, 97045
- Providence Willamette Falls Medical Center
-
Portland, Oregon, Соединенные Штаты, 97239
- Oregon Health and Science University
-
Portland, Oregon, Соединенные Штаты, 97213
- Providence Portland Medical Center
-
Portland, Oregon, Соединенные Штаты, 97225
- Providence Saint Vincent Medical Center
-
Redmond, Oregon, Соединенные Штаты, 97756
- Saint Charles Health System-Redmond
-
-
Pennsylvania
-
Allentown, Pennsylvania, Соединенные Штаты, 18103
- Lehigh Valley Hospital-Cedar Crest
-
Bethlehem, Pennsylvania, Соединенные Штаты, 18017
- Lehigh Valley Hospital - Muhlenberg
-
East Stroudsburg, Pennsylvania, Соединенные Штаты, 18301
- Pocono Medical Center
-
Hazleton, Pennsylvania, Соединенные Штаты, 18201
- Lehigh Valley Hospital-Hazleton
-
-
Texas
-
Austin, Texas, Соединенные Штаты, 78723
- Dell Children's Medical Center of Central Texas
-
-
Utah
-
Farmington, Utah, Соединенные Штаты, 84025
- Farmington Health Center
-
Salt Lake City, Utah, Соединенные Штаты, 84112
- Huntsman Cancer Institute/University of Utah
-
Salt Lake City, Utah, Соединенные Штаты, 84106
- University of Utah Sugarhouse Health Center
-
-
Virginia
-
Charlottesville, Virginia, Соединенные Штаты, 22908
- University of Virginia Cancer Center
-
-
Washington
-
Aberdeen, Washington, Соединенные Штаты, 98520
- Providence Regional Cancer System-Aberdeen
-
Bellingham, Washington, Соединенные Штаты, 98225
- PeaceHealth Saint Joseph Medical Center
-
Centralia, Washington, Соединенные Штаты, 98531
- Providence Regional Cancer System-Centralia
-
Edmonds, Washington, Соединенные Штаты, 98026
- Swedish Cancer Institute-Edmonds
-
Everett, Washington, Соединенные Штаты, 98201
- Providence Regional Cancer Partnership
-
Issaquah, Washington, Соединенные Штаты, 98029
- Swedish Cancer Institute-Issaquah
-
Kennewick, Washington, Соединенные Штаты, 99336
- Kadlec Clinic Hematology and Oncology
-
Lacey, Washington, Соединенные Штаты, 98503
- Providence Regional Cancer System-Lacey
-
Longview, Washington, Соединенные Штаты, 98632
- PeaceHealth Saint John Medical Center
-
Seattle, Washington, Соединенные Штаты, 98107
- Swedish Medical Center-Ballard Campus
-
Seattle, Washington, Соединенные Штаты, 98122
- Swedish Medical Center-First Hill
-
Seattle, Washington, Соединенные Штаты, 98104
- Pacific Gynecology Specialists
-
Seattle, Washington, Соединенные Штаты, 98122-5711
- Swedish Medical Center-Cherry Hill
-
Sedro-Woolley, Washington, Соединенные Штаты, 98284
- PeaceHealth United General Medical Center
-
Shelton, Washington, Соединенные Штаты, 98584
- Providence Regional Cancer System-Shelton
-
Vancouver, Washington, Соединенные Штаты, 98664
- PeaceHealth Southwest Medical Center
-
Walla Walla, Washington, Соединенные Штаты, 99362
- Providence Saint Mary Regional Cancer Center
-
Yelm, Washington, Соединенные Штаты, 98597
- Providence Regional Cancer System-Yelm
-
-
Wisconsin
-
New Richmond, Wisconsin, Соединенные Штаты, 54017
- Cancer Center of Western Wisconsin
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
-
Documentation of disease
- Histologic documentation: Histologically-proven advanced (metastatic or unresectable primary) pheochromocytoma or paraganglioma
- Stage: Advanced (metastatic or unresectable primary) disease
- Tumor site: Histologically-proven pheochromocytoma or paraganglioma
- Radiographic evaluation: Radiographic evidence of disease progression by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 in the 12 months prior to registration
-
Measurable disease
- Lesions must be accurately measured in at least one dimension (longest diameter to be recorded) as >= 1 cm with CT or MRI (or >= 1.5 cm for lymph nodes). Non-measurable disease includes disease smaller than these dimensions or lesions considered truly non-measurable including: leptomeningeal disease, ascites, pleural or pericardial effusion, lymphangitic involvement of skin or lung
-
Prior treatment with other somatostatin analog, chemotherapy, radiotherapy (including peptide radionuclide receptor therapy [PRRT]), or surgery must be completed >= 28 days prior to registration. Patients must have recovered from any effects of any major surgery prior to registration
-
Prior treatment with radiolabeled metaiodobenzylguanidine (MIBG) must be completed >= 12 weeks prior to registration and lifetime cumulative 131I-MIBG dose must be < 1000 MBq kg^-1 (36 mCi kg^-1)
-
Prior treatment with antibiotics must be completed >= 7 days prior to registration
-
No prior treatment with temozolomide, dacarbazine, or a poly ADP ribose polymerase (PARP) inhibitor
-
No prior allogeneic bone marrow transplant or double umbilical cord blood transplantation (dUCBT)
-
Not pregnant and not nursing, because this study involves an agent that has known genotoxic, mutagenic, and teratogenic effects. Therefore, for women of childbearing potential only, a negative pregnancy test done =< 7 days prior to registration is required
-
Contraception
- Therapy utilized in this trial is associated with medium/high fetal risk
- Women of childbearing potential and their partners, who are sexually active, must agree to use two highly effective forms of contraception in combination. This should be started from the time of registration and continue throughout the period of taking study treatment and for at least 1 month after last dose of study drug(s), or they must totally/truly abstain from any form of sexual intercourse
- Male patients must use a condom during treatment and for 3 months after the last dose of study drug(s) when having sexual intercourse with a pregnant woman or with a woman of childbearing potential. Female partners of male patients should also use a highly effective form of contraception if they are of childbearing potential. Male patients should not donate sperm throughout the period of taking study drug(s) and for 3 months following the last dose of study drug(s)
-
Age >= 12 years
-
Eastern Cooperative Oncology Group (ECOG) Patients ≥ 18 years of age: Performance status: 0-2
- Patients < 16 years of age: Lansky ≥ 50%
- Patients 16 to < 18 years of age: Karnofsky ≥ 50%
- Patients ≥ 18 years of age: ECOG performance status ≤ 2
-
Absolute neutrophil count >= 1,500/mm^3
-
Platelet count >= 100,000/mm^3
-
Hemoglobin >= 10 mg/dL if prior radionuclide therapy Hemoglobin >= 8 mg/dL if no prior radionuclide therapy
- In the absence of transfusion within the previous 24 hours. Radionuclide therapy includes PRRT or MIBG
-
Total bilirubin =< 1.5 x upper limit of normal (ULN)
- Except in the case of Gilbert's syndrome, then total bilirubin must be =< 3.0 x ULN
-
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3.0 x ULN
-
Creatinine < 1.5 x ULN OR calculated (calc.) creatinine clearance > 50 mL/min
-
Calculated by Cockcroft-Gault equation
-
By Cockcroft-Gault equation. Alternatively, for patients < 18 years of age, maximum serum creatinine ≤ the below age-sex-specific norms:
- Age 12 years: Male 1.2; female 1.2
- Age 13 to < 16 years: Male 1.5; female 1.4
- Age 16 to < 18 years: Male 1.7; female 1.4
-
-
No indication of uncontrolled, potentially reversible cardiac condition(s) as determined by investigator (e.g., unstable ischemia, uncontrolled symptomatic arrhythmia, congestive heart failure, Fridericia's formula-corrected QT interval [QTcF] prolongation > 500 msec, electrolyte disturbances, etc.) and no known congenital long QT syndrome
-
No extensive bilateral lung disease or pneumonitis
-
No abnormal organ or bone marrow function =< 28 days prior to registration
-
Patients with human immunodeficiency virus (HIV) positivity are allowed if CD4 count > 250 cells/uL and they have an undetectable HIV viral load within 6 months of registration
-
No active infection
-
No history of myelodysplastic syndrome (MDS) (or any dysplastic leukocyte morphology suggestive of MDS) or acute myeloid leukemia
-
No known gastrointestinal condition(s) that might predispose for drug intolerability or poor drug absorption
-
No known medical condition causing an inability to swallow oral formulations of agents
-
No history of allergic reaction attributed to compounds of similar chemical or biologic composition to PARP inhibitors
-
Concurrent use of combination antiretroviral therapy (ART) is not permitted
-
Chronic concomitant treatment with strong or moderate CYP3A4 inducers or inhibitors is not allowed. Patients must discontinue the agent(s) >= 21 days prior to registration; enzalutamide and/or phenobarbital must be discontinued >= 5 weeks prior to registration
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Arm I (temozolomide, olaparib)
Patients receive temozolomide PO QD and olaparib PO BID on days 1-7. Treatment with temozolomide repeats every 21 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Cycles of olaparib repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT with contrast or MRI throughout the study and undergo mandatory collection of blood samples prior to treatment. Patients may optionally undergo collection of blood samples at the time of progression. |
Ancillary studies
Другие имена:
Undergo MRI
Другие имена:
Given PO
Другие имена:
Undergo collection of blood samples
Другие имена:
Given PO
Другие имена:
Undergo CT with contrast
Другие имена:
|
|
Активный компаратор: Arm II (temozolomide)
Patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with contrast or MRI throughout the study and undergo mandatory collection of blood samples prior to treatment. Patients may optionally undergo collection of blood samples at the time of progression. |
Ancillary studies
Другие имена:
Undergo MRI
Другие имена:
Given PO
Другие имена:
Undergo collection of blood samples
Другие имена:
Undergo CT with contrast
Другие имена:
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Progression-free survival (PFS)
Временное ограничение: From randomization to the first documentation of disease progression (per Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1) or death, assessed up to 5 years
|
Will be compared between treatment arms using the un-stratified log-rank test at one-sided level of 0.11 and the p-value will be used for decision making. The hazard ratio will be estimated using a Cox proportional hazards model and the 95% confidence interval for the hazard ratio will be provided. Results from a stratified analysis will also be provided. Kaplan-Meier methodology will be used to estimate the median PFS for each treatment arm, and Kaplan-Meier curves will be produced. Brookmeyer-Crowley methodology will be used to construct the 95% confidence interval for the median PFS for each treatment arm. |
From randomization to the first documentation of disease progression (per Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1) or death, assessed up to 5 years
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Overall survival (OS)
Временное ограничение: From randomization to death due to any cause, assessed up to 5 years
|
Patients who are alive will be censored at last follow-up. The distribution of survival time will be estimated using the method of Kaplan-Meier. OS will be compared between treatment arms using the log-rank test. OS medians, survival rates and hazard ratio will be estimated along with 95% confidence intervals. |
From randomization to death due to any cause, assessed up to 5 years
|
|
Objective response
Временное ограничение: Up to 5 years
|
Will be assessed by RECIST version 1.1 criteria. Will be estimated using objective response rate where objective response rate is defined as the number of evaluable patients achieving a response (partial response or complete response per RECIST version 1.1) during treatment with study therapy divided by the total number of evaluable patients. Rates of response will be compared across arms using a Chi-Square Test for Proportion. Point estimates will be generated for objective response rates within each arm along with 95% binomial confidence intervals. |
Up to 5 years
|
|
Incidence of adverse events
Временное ограничение: Up to 5 years
|
Will be assessed per National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The term toxicity is defined as adverse events that are classified as possibly, probably, or definitely related to study treatment. Toxicities will be evaluated via the ordinal Common Terminology Criteria for Adverse Events standard toxicity grading. Similarly, scores (0-4) and the maximum score for each Patient-Reported Outcomes-CTCAE item will be recorded for each patient. |
Up to 5 years
|
Другие показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Biochemical response
Временное ограничение: Up to 5 years
|
Levels of chromogranin A, urine and/or plasma catecholamines and metanephrines may predict response to therapy. The proportion of patients with a biochemical response of partial response or better, as determined by plasma and/or urine catecholamines and metanephrines, will be calculated, and a 95% confidence interval will be placed on this proportion. For each factor, we will calculate the mean +/- standard deviation, minimum, maximum, and quartiles; in addition, we will generate box and whisker plot. |
Up to 5 years
|
|
Biomolecular markers associated with clinical outcome
Временное ограничение: Up to 5 years
|
Will analyze for methyltransferase (MGMT) methylation expression in archival tumors and correlate with the radiographic response rate in metastatic pheochromocytoma/paraganglioma. This is hypothesis generated box and whisker plot. |
Up to 5 years
|
Соавторы и исследователи
Спонсор
Следователи
- Главный следователь: Jaydira Del Rivero, Alliance for Clinical Trials in Oncology
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
- Новообразования
- Новообразования по гистологическому типу
- Нейроэктодермальные опухоли
- Новообразования, зародышевые клетки и эмбриональные
- Новообразования, нервная ткань
- Нейроэндокринные опухоли
- Феохромоцитома
- Параганглиома
- Органические химические вещества
- Гетероциклические соединения, 1-кольцо
- Гетероциклические соединения
- Следственные методы
- Клинические лабораторные методы
- Диагностические методы и процедуры
- Диагноз
- Азолы
- Фармакологические действия
- Химические действия и используют
- Дакарбазин
- Триазены
- Имидазолы
- Специальное использование химических веществ
- Химические методы, аналитические
- Анализ спектра
- Диагностическое использование химических веществ
- Темозоломид
- Обработка образца
- Магнитно -резонансная спектроскопия
- Олапариб
- Контрастные СМИ
Другие идентификационные номера исследования
- NCI-2020-03379
- U10CA180821 (Грант/контракт NIH США)
- NCI-2020-03379 (Идентификатор реестра: CTRP (Clinical Trial Reporting Program))
- A021804 (Другой идентификатор: CTEP)
- A021804 (Другой идентификатор: Alliance for Clinical Trials in Oncology)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .